Sutro Biopharma STRO Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's accretion (amortization) of discounts and premiums, investments?
- Sutro Biopharma (STRO) reported accretion (amortization) of discounts and premiums, investments of $445K in Q1 2026.
- How has Sutro Biopharma's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Sutro Biopharma's accretion (amortization) of discounts and premiums, investments decreased by 60.1% year-over-year, from $1.12M to $445K.
- What is the long-term trend for Sutro Biopharma's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Sutro Biopharma's accretion (amortization) of discounts and premiums, investments has grown at a 5.4% compound annual growth rate (CAGR), from -$2.78M to $3.44M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to interest income or expense resulting from the amortization of discounts or premiums on debt securities held as investments. It reflects the gradual recognition of the difference between the purchase price and the face value of investment securities over their holding period. This adjustment is necessary to reconcile net income with actual cash flows from operating activities.